CA
CORT icon

Claris Advisors’s Corcept Therapeutics CORT Stock Holding History

Claris Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6
Closed -$278 – 301
2024
Q3 		$278 Buy
+6
New +$213 ﹤0.01% 858

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Claris Advisors's CORT Position: Q4 2024 in Review

Claris Advisors sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 6 shares — an estimated $278 sold.

Claris Advisors first reported a position in CORT in Q3 2024 and held it in 1 quarter. The position peaked at $278 in Q3 2024. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Claris Advisors reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 6 Corcept Therapeutics shares in Q4 2024, an estimated $278.
  • Claris Advisors first reported a position in Corcept Therapeutics in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Corcept Therapeutics position peaked at $278 in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.